UK warns about differences between Tazocin and its generics
This article was originally published in Scrip
Executive Summary
There are formulation differences between a branded injectable antibacterial product,Wyeth's Tazocin (piperacillin plus tazobactam), and recently approved generic versions that have the potential to cause serious medication errors because the generics have different compatibilities with other medicines compared with Tazocin, the UK regulator, the MHRA,has warned. Tazocin was reformulated last year, the agency notes.